Established cell lines isolated from human skin fibroblasts from patients with defined autism spectrum disorders (ASDs) or unaffected volunteers (control group).
Autism spectrum disorders (ASDs) comprise a set of neurodevelopmental disorders that are, at best, poorly understood but are the fastest growing developmental disorders in the United States. Derivation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming offers an alternative strategy for identifying the cellular mechanisms contributing to ASDs and the development of new treatment options.
From the laboratory of Philip H. Schwartz, PhD, Children's Hospital of Orange County.
|Product Type:||Cell Line|
|Name:||Autism Spectrum Disorder (ASD) Cell Lines|
|Subculturing:||5-7 days doubling time, change medium every 2-3 days. Recommended split ratio of 1:2 or 1:3 in new TC-treated flasks.|
|Growth Conditions:||Human Dermal Fibroblast Medium [HDFM; D-MEM high glucose with GlutaMAX (Life Technologies (10569), 10% Certified FBS (Life Technologies 16000), 1X non-essential amino acids (NEAA; Hyclone), and 10uM Primocin (InvivoGen)]. Incubate at 37C, 5% CO2.|
|Cryopreservation:||80% HDFM, 10% FBS, 10% DMSO|
Control Lines: sc148, sc160, sc164, sc178, sc197, sc231
Idiopathic Autism Lines: sc119 sc166, sc174, sc204, sc222, sc229
If you publish research with this product, please let us know so we can cite your paper.